ICON named best Contract Research Organisation in latest string of awards and recognitions
ICON and its drug and device development work continues to be recognised by peers, employees, and organisations around the globe
ICON Releases Environmental, Social and Governance Report
ICON announced the release of its 2020 Environmental, Social and Governance Report. The report looks to the future of ESG for the new ICON while highlighting advancements made in 2020.
ICON announces the expansion of its Accellacare Site Network
New partnerships increase geographical footprint, supporting more access to patients and strengthening therapeutic capability
ICON plc to Present at the 30th Annual Credit Suisse Healthcare Conference and the 4th Annual Evercore ISI HealthCONx Conference
Tuesday, November 9, 2021 at 8.50am ET
ICON reports third quarter 2021 financial results
Quarter 3 adjusted revenue of $1,870.4 million representing a year on year increase of 167% or 165% on a constant currency basis.
Tánaiste announces multi-million Euro R&D support of ICON to accelerate decentralised clinical trial technology
The R&D support will help development of tech-enabled systems that provide greater flexibility and reduce the burden felt by clinical trial participants.
ICON plc to present at the Wells Fargo 16th Annual Healthcare Conference and the Baird Global Healthcare Conference
Thursday, September 9, 2021 at 8.00am ET
ICON reports second quarter 2021 financial results
Quarter 2 reported revenue of $871.2 million representing a year on year increase of 40.5% and 1.5% increase on Quarter 1 2021.
ICON acquisition creates world-leading healthcare intelligence and clinical research organisation
The combined company will leverage its enhanced operations to transform clinical trials and accelerate biopharma customer’s commercial success through the development of medicines and medical devices.
ICON shareholders vote in favour of all resolutions at its Extraordinary General Meeting
All resolutions at the ICON Extraordinary General Meeting held on June 15, 2021 (which resolutions had all been recommended by the Board) were all duly passed by shareholders.